Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal β2-agonist

K. Akamatsu, T. Yamagata, T. Takahashi, K. Miura, S. Maeda, Y. Yamagata, T. Ichikawa, S. Yanagisawa, K. Ueshima, T. Hirano, M. Nakanishi, K. Matsunaga, Y. Minakata, M. Ichinose

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Background: A combination of bronchodilators may be effective in the treatment of chronic obstructive pulmonary disease (COPD). We examined the effect of adding a long-acting anti-cholinergic agent (tiotropium) to a transdermal-type β2-agonist (tulobuterol) on dyspnea as well as pulmonary function. Methods: In a multicentre, randomized, parallel design study, 60 COPD patients treated with the transdermal β2-agonist tulobuterol were divided into a tiotropium added group (Tulo+Tio group, n = 40) or transdermal β2-agonist tulobuterol alone group (Tulo group, n = 20), and then treated for 4 weeks after a 2 week run-in period. Pulmonary function and a dyspnea (Medical Research Council (MRC)) scale were assessed before and after the treatment. Daily peak expiratory flow (PEF) monitoring was also performed. Results: After 4 weeks, the Tulo+Tio group showed a significant increase in pulmonary function compared with the Tulo group; ΔFVC (0.31±0.06 L vs. 0.06±0.05 L, p< 0.01), ΔFEV1 (0.15±0.03 L vs. -0.02±0.02 L, p<0.0001), and ΔPEF (41.0±5.1 L/min vs. 0.5±3.5 L/min, p<0.0001). The MRC dyspnea scale was also significantly improved in Tulo+Tio, but not in Tulo group. Conclusion: These results suggest that tiotropium caused a significant improvement in both pulmonary function and dyspnea in COPD patients already treated with the transdermal β2-agonist tulobuterol.

Original languageEnglish
Pages (from-to)701-707
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Issue number6
Publication statusPublished - 2007 Dec


  • Combination therapy
  • Dyspnea
  • Pulmonary function
  • Tiotropium
  • Transdermal β-agonist tulobuterol


Dive into the research topics of 'Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal β2-agonist'. Together they form a unique fingerprint.

Cite this